Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
White House Seeks $1.4 Billion to Combat Growing Ebola Outbreak 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
Takeda Hit With $885M Verdict Over Amitiza Generic Drug Delay Scheme 
UNAIDS Urges U.S. to Reconsider South Africa HIV Funding Withdrawal 
Apple Tests China’s CXMT Memory Chips for iPhones and MacBooks Amid AI Supply Crunch 
Goldman Sachs Sees US Stock Buybacks Outpacing Equity Issuance as AI Funding Rises 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
FDA Investigates New Cyclospora Outbreak as U.S. Cases Continue to Rise 
US Tightens Ebola Controls as Congo Outbreak Sparks Global Concern 
Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 
The government is ‘doubling down’ on its social media ban. But bigger penalties for platforms aren’t enough 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
Sony, TSMC Eye $6.3 Billion Japan Chip Venture for Next-Gen Image Sensors 
Danish pharmaceutical giant Novo Nordisk has officially launched its once-daily Wegovy weight-loss pill in the United States, intensifying competition in the rapidly growing obesity drug market. The oral medication, approved by the U.S. Food and Drug Administration last month, will be available starting Monday and is aimed largely at self-paying patients seeking alternatives to injectable treatments.
Novo Nordisk is initially offering Wegovy pill doses of 1.5 milligrams and 4 milligrams at a price of $149 per month for cash-paying customers. However, pricing will rise over time, with the 4 mg dose increasing to $199 per month from April 15. Higher doses of 9 mg and a long-term maintenance dose of 25 mg will be priced at $299 per month. The pill contains semaglutide, the same active ingredient used in Novo’s injectable Wegovy and Ozempic, as well as its diabetes pill Rybelsus.
The launch is seen as a strategic move by Novo to regain momentum after profit warnings and share price declines last year, particularly as U.S. rival Eli Lilly continues to gain ground with its injectable obesity drug Zepbound. Lilly is also developing its own weight-loss pill, with an FDA decision expected in March. Investors reacted positively to Novo’s announcement, sending its Denmark-listed shares up 5% and U.S.-listed shares up 4.6%, while Lilly shares slipped.
Novo Nordisk is positioning the Wegovy pill as a more flexible and needle-free option, potentially attracting new consumers who are hesitant about injections. The company emphasized that success will depend heavily on attracting cash-paying customers, as insurance coverage for weight-loss drugs remains limited in the U.S.
The Wegovy pill will be distributed through major pharmacies such as CVS and Costco, along with telehealth platforms including Ro, LifeMD, WeightWatchers, GoodRx, and NovoCare Pharmacy. Telehealth stocks surged following the announcement, reflecting optimism around increased demand.
Novo also stated it has built sufficient inventory to avoid the supply shortages that previously plagued its injectable Wegovy rollout. Additionally, under an agreement with U.S. President Donald Trump, Novo and Eli Lilly will offer starter doses of their weight-loss pills at $149 per month to Medicare and Medicaid enrollees and through the upcoming TrumpRx direct-to-consumer platform.
